Cyclacel Pharmaceuticals Files 10-K/A Amendment

TL;DR

<b>Cyclacel Pharmaceuticals, Inc. has filed an amendment to its 2023 annual report, confirming its compliance with SEC filing requirements.</b>

AI Summary

Cyclacel Pharmaceuticals, Inc. (BGMSP) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Cyclacel Pharmaceuticals, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located in Berkeley Heights, New Jersey. Common stock (CYCC) and Preferred Stock (CYCCP) are registered and traded on The Nasdaq Capital Market. The filing indicates the company has met its filing requirements for the past 12 months and 90 days. Cyclacel Pharmaceuticals, Inc. has submitted all required Interactive Data Files electronically for the preceding 12 months.

Why It Matters

For investors and stakeholders tracking Cyclacel Pharmaceuticals, Inc., this filing contains several important signals. This amendment to the 10-K filing suggests potential updates or corrections to the company's previously submitted annual financial and operational data. The confirmation of compliance with filing requirements is a standard procedural update, but crucial for maintaining good standing with the SEC and investor confidence.

Risk Assessment

Risk Level: low — Cyclacel Pharmaceuticals, Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, which is a routine update and does not inherently signal significant new risks or positive developments beyond standard reporting.

Analyst Insight

Monitor for the specific details within the 10-K/A amendment to understand any changes in financial status, operational disclosures, or risk factors.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reported fiscal year end)
• 2024-04-29 — Filing Date (Date the amendment was filed)

Key Players & Entities

• Cyclacel Pharmaceuticals, Inc. (company) — Filer name
• The Nasdaq Capital Market (company) — Exchange where securities are registered
• CYCC (company) — Trading symbol for Common Stock
• CYCCP (company) — Trading symbol for Preferred Stock
• Delaware (company) — State of incorporation
• Berkeley Heights, New Jersey (company) — Location of principal executive offices

FAQ

Industry Context

Cyclacel Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of drugs.

Regulatory Implications

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments.

What Investors Should Do

1. Review the full 10-K/A filing for specific amendments and updated financial data.
2. Track future SEC filings from Cyclacel Pharmaceuticals for ongoing operational and financial transparency.
3. Analyze the company's performance and strategic direction in the context of its industry and regulatory environment.

Year-Over-Year Comparison

This is an amended 10-K filing for the fiscal year ended December 31, 2023, indicating updates or corrections to the original submission.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital M
• $8.84 — 23 (based upon the closing sale price of$8.84 of such shares on The NASDAQ Capital Ma
• $2.7 billion — of ArQule Inc., which was acquired for $2.7 billion by Merck & Co. in 2020. Prior to ArQule

Filing Documents

• cycc-20231231x10ka.htm (10-K/A) — 547KB
• cycc-20231231xex31d1.htm (EX-31.1) — 13KB
• cycc-20231231xex31d2.htm (EX-31.2) — 13KB
• 0001558370-24-006141.txt (&nbsp;) — 873KB
• cycc-20231231.xsd (EX-101.SCH) — 4KB
• cycc-20231231_def.xml (EX-101.DEF) — 45KB
• cycc-20231231_lab.xml (EX-101.LAB) — 23KB
• cycc-20231231_pre.xml (EX-101.PRE) — 21KB
• cycc-20231231x10ka_htm.xml (XML) — 11KB

Executive Compensation

Executive Compensation 10 I tem 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 18 I tem 13. Certain Relationships and Related Transactions, and Director Independence 20 I tem 14. Principal Accountant Fees and Services 21 PART IV Item 15. Exhibits and Financial Statement Schedules 23 3 Table of Contents PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance The Board of Directors Our charter provides that our business is to be managed by or under the direction of our Board of Directors. Our Board of Directors is divided into three classes for purposes of election. One class is elected at each annual meeting of stockholders to serve for a three-year term. Our Board of Directors currently consists of three classes, as set forth below. We also have two directors who are elected by holders of our 6% Convertible Exchangeable Preferred Stock (the "Preferred Stock"), Set forth below, as of December 31, 2023, are the names of our directors, their ages, their offices in the Company, if any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which such persons hold or have held directorships during the past five years. Additionally, information about the specific experience, qualifications, attributes or skills that led to our Board of Directors' conclusion at the time of filing of this proxy statement that each person listed below should serve as a director is set forth below: Name Age Position Spiro Rombotis 65 President and Chief Executive Officer; Class 2 Director Paul McBarron 63 Executive Vice President—Finance, Chief Financial Officer, Chief Operating Officer and Secretary; Class 3 Director Nominee Dr. Christopher Henney 83 Chairman; Class 3 Director Nominee Dr. Robert Spiegel 74 Vice Chairman; Class 3 Director Nominee Dr. Samuel L. Barker 81 Class 2 Director on behalf of our holders of Preferred Stock Dr. Kenneth M. Ferguson 68 Class 1 Director on behalf of our holders of Preferred Stock Dr. Brian Schwartz 62 Class 2 Director; Interim Chief Medical Officer Karin L. Walker 60 Class 1 Director Board Diversity Matrix (as of April 23, 2024) This table provides information on the diversity of

: Gender Identity

Part I: Gender Identity

: Demographic Background

Part II: Demographic Background White 6 1 Did not Disclose Demographic Background 1 Class 1 Director (Term to Expire in 2025) Karin L. Walker . Ms. Walker has served as a director of the Company since November 2020 and has over 30 years of extensive finance experience in biopharmaceuticals, including in public biotechnology companies and technology companies. Ms. Walker currently serves as the Chief Accounting Officer of Prothena Corporation plc, a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics focused on neurodegenerative and rare peripheral amyloid diseases, and has held this position since 2013. Prior to joining Prothena, she was Vice President, Finance and Chief Accounting Officer of Affymax, Inc., a position she held from 2012 to 2013. From 2009 to 2012, Ms. Walker was Vice President, Finance and Corporate Controller at Amyris Inc. From 2006 to 2009, she was Vice President, Finance and Corporate Controller for CV Therapeutics, Inc. Ms. Walker also held senior financial leadership positions at Knight Ridder Digital, Accellion, 4 Table of Contents Niku Corporation, Financial Engines, Inc. and NeoMagic Corporation. Ms. Walker also served as a director and Audit Committee Chair for LifeSci Acquisition Corp. (a publicly-traded special purpose acquisition company) in 2020. Ms. Walker earned her B.S. in business from the California State Polytechnic University, San Luis Obispo, and is a certified public accountant (CPA). We believe that Ms. Walker's qualifications to serve on the Board of Directors include experience in the biotechnology and pharmaceutical industry and her many years' experience in finance. Class 2 Directors (Terms to expire in 2026) Spiro Rombotis . Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has over 38 years at three public biotechs and two pharmas. He participated in in-licensing, clinical development, regulatory approval, partnerin

View Full Filing

View this 10-K/A filing on SEC EDGAR